Search clinical trials for: Vaniprevir

Total 47 results

Merck Sharp & Dohme LLC

Completed

A Study Investigating the Influence of Hepatic Insufficiency on the Pharmacokinetics of Vaniprevir (MK-7009-005)

Hepatitis C
Merck Sharp & Dohme LLC

Terminated

Pharmacokinetics of Vaniprevir (MK-7009) and Hepatitis C Virus RNA Levels After Vaniprevir Treatment (MK-7009-029)

Chronic Hepatitis C Infection
Merck Sharp & Dohme LLC

Withdrawn

Study to Evaluate Different Regimens of Vaniprevir (MK7009) for the Treatment of Chronic Genotype 1 Hepatitis C Virus Infection in Treatment-naive Patients (MK-7009-019)(WITHDRAWN)

Chronic Genotype 1 Hepatitis C Virus Infection
Merck Sharp & Dohme LLC

Completed

Vaniprevir Administered With Pegylated-interferon and Ribavirin in Japanese Treatment-Naïve Chronic Hepatitis C Participants (MK-7009-043)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

A Study of Vaniprevir (MK-7009) in Participants With Chronic Hepatitis C Infection After Participation in Other Vaniprevir Studies (MK-7009-028)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

Evaluating Fine Needle Aspiration to Measure Hepatic Vaniprevir (MK-7009) Concentrations in Participants With Chronic Hepatitis C (MK-7009-048)

Chronic Hepatitis C
Hoffmann-La Roche

Completed

A Study of Combination Treatment With an HCV Polymerase Inhibitor (RO5024048) and an HCV Protease Inhibitor (RO5190591/Danoprevir) in Genotype 1 Chronic Hepatitis C Patients

Hepatitis C, Chronic

New Zealand, Australia
Merck Sharp & Dohme LLC

Completed

Study of Vaniprevir Plus PegIntron®/Ribavirin in Japanese Participants With Chronic Hepatitis C Who Relapsed After Treatment (MK-7009-044)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

Vaniprevir Plus PegIntron®/Ribavirin in Japanese Participants With Chronic Hepatitis C Who Are Non-responders to Previous Treatment (MK-7009-045)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

A Study of Safety and Efficacy of Vaniprevir Administered With Pegylated-Interferon and Ribavirin in Japanese Participants With Chronic Hepatitis C Infection (7009-016)

Hepatitis C
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy of Vaniprevir (MK7009) Administered With Pegylated-Interferon and Ribavirin (MK-7009-007)

Hepatitis C
Hoffmann-La Roche

Completed

A Study of RO5190591 (Danoprevir) in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection

Hepatitis C, Chronic

United States, Canada, Australia, France, Germany, Austria, Italy
University of Extremadura

Active, not recruiting

Influence of Co-diagnosis of Chronic Fatigue Syndrome in Patients With Fibromyalgia.

Fibromyalgia | Chronic Fatigue Syndrome | Comorbidities and Coexisting Conditions

Spain
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy of Vaniprevir (MK-7009) With Pegylated Interferon (Peg-IFN) and Ribavirin (RBV) in Treatment-Experienced Hepatitis C Virus (HCV) Participants (MK-7009-009)

Hepatitis C, Chronic
Tanta University

Completed

Efficacy of Faviprevir in COVID-19 Treatment

COVID

Egypt
Ascletis Pharmaceuticals Co., Ltd.

Completed

Efficacy and Safety of Ravidasvir in Combination With Danoprevir/r and Ribavirin(RBV) in Treatment-naive, Non-cirrhotic, Chronic Hepatitis C Virus Genotype1 Infected Subjects.

HCV

China
Damascus University

Completed

The Role of Paracetamol-caffeine and Laser Irradiation on Controlling Pain and Discomfort During Orthodontic Treatment

Orthodontic Appliance Complication | Pain and Discomfort

Syrian Arab Republic
Hoffmann-La Roche

Completed

A Study of Danoprevir in Combination With Low-Dose Ritonavir in Healthy Subjects

Healthy Volunteer

France
Huoshenshan Hospital
Ascletis Pharmaceuticals Co., Ltd.

Completed

Efficacy and Safety of Ganovo (Danoprevir) Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection

COVID-19

China
Hoffmann-La Roche

Completed

A Safety And Pharmacokinetic Study of Setrobuvir Alone and In Combination With Ritonavir-Boosted Danoprevir in Subjects With Mild Hepatic Impairment Compared to Healthy Controls

Healthy Volunteer

Poland, Hungary
Hoffmann-La Roche

Completed

A Study of Danoprevir in Healthy Volunteers And Patients With Hepatic Impairment

Healthy Volunteer

Slovakia, United States, Czech Republic
Hoffmann-La Roche

Completed

A Study of Drug-Drug Interaction Between Darunavir and Danoprevir Administered Together With Low-Dose Ritonavir in Healthy Volunteers

Healthy Volunteer

United States
Ascletis Pharmaceuticals Co., Ltd.

Completed

Safety, Tolerability and Pharmacokinetics of Danoprevir/r in Healthy Volunteers China

Healthy
Qing XIe
Gilead Sciences; Tigermed Consulting Co., Ltd

Recruiting

Effectiveness and Safety of Direct-Acting Antiviral Agents for the Treatment of Chronic Hepatitis C (C-DIAMOND)

Hepatitis C, Chronic

China
Ascletis Pharmaceuticals Co., Ltd.

Completed

Pharmacokinetics and Safety of ASC16 Tablets in Healthy Volunteers in China

HCV

China
Hoffmann-La Roche

Completed

A Relative Bioavailability Study of Danoprevir and Ritonavir in Healthy Volunteers

Healthy Volunteer

New Zealand
Ascletis Pharmaceuticals Co., Ltd.

Completed

Efficacy and Safety of Ravidasvir + Danoprevir/r 12-week Oral Therapy in Treatment-Naive Non Cirrhotic G1 CHC Taiwan

Chronic Hepatitis C
Ascletis Pharmaceuticals Co., Ltd.

Completed

Pharmacokinetics and Safety of Ravidasvir and Danoprevir/r in Healthy Volunteers China

Healthy
Hoffmann-La Roche

Completed

A Study of The Relative Bioavailability of Ritonavir-Boosted Danoprevir Fixed Dose Combination Tablets in Healthy Volunteers

Healthy Volunteer

New Zealand
Hoffmann-La Roche

Completed

A Study of Drug-Drug Interaction Between Danoprevir/Low-Dose Ritonavir and Raltegravir in Healthy Volunteers

Healthy Volunteer

United States
Hoffmann-La Roche

Completed

A Pharmacokinetic And Bioavailability Study of Intravenous Danoprevir in Healthy Volunteers

Healthy Volunteer

Netherlands
Hoffmann-La Roche

Completed

A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection

Hepatitis C, Chronic

France, Germany, United States, Spain, Canada, Austria, United Kingdom, Puerto Rico, Italy, Brazil, Mexico
Hoffmann-La Roche

Completed

A Study of Ritonavir-Boosted Danoprevir (RO5190591) in Combination With Pegasys and Ribavirin in Patients With Chronic Hepatitis C Genotype 1

Hepatitis C, Chronic

New Zealand, Poland, France
Hoffmann-La Roche

Completed

A Study of Ritonavir-Boosted Danoprevir and RO5024048 in Different Combinations in Null Responder or Treatment-Naïve Patients With Chronic Hepatitis C and Compensated Cirrhosis

Hepatitis C, Chronic

United States, Canada, Slovakia, Poland, New Zealand, France, Australia
Hoffmann-La Roche

Withdrawn

A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C Genotype 1 Who Have Failed Prior HCV Protease Inhibitor Treatment

Hepatitis C, Chronic
Ascletis Pharmaceuticals Co., Ltd.

Completed

Efficacy and Safety of Danoprevir/r + PR 12week Triple Therapy in Treatment Naive Non-Cirrhotic G1 CHC China III

Chronic Hepatitis C
Ascletis Pharmaceuticals Co., Ltd.

Completed

Efficacy and Safety of Danoprevir/r + PR 12-week Triple Therapy in Treatment-Naive, Non-Cirrhotic, G1 CHC China II

Chronic Hepatitis C
Hoffmann-La Roche

Completed

A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir With or Without Copegus (Ribavirin) in Interferon-Naïve Patients With Chronic Hepatitis C Genotype 1 (INFORM-SVR)

Hepatitis C, Chronic

France, Germany, United States, New Zealand
Hoffmann-La Roche

Completed

A Drug-Drug Interaction Study Between Danoprevir/Low-Dose Ritonavir and Cyclosporine in Healthy Volunteers

Healthy Volunteer

United States
Hoffmann-La Roche

Completed

A Study of Danoprevir/Ritonavir and Copegus With RO5024048 and/or Pegasys in Patients With Chronic Hepatitis C

Hepatitis C, Chronic

United States, Spain, France, Canada, Germany, Austria, Australia, Brazil, United Kingdom, Italy, Mexico, Poland, Puerto Rico
Hoffmann-La Roche

Completed

A Study of Drug-Drug Interaction Between Danoprevir Coadministered With Low-Dose Ritonavir and Tenofovir Disoproxil Fumarate or Atazanavir

Healthy Volunteer

United States
Hoffmann-La Roche

Completed

A Study of RO5190591 (Danoprevir) in Healthy Volunteers

Healthy Volunteer

United States
Hoffmann-La Roche

Completed

A Study to Evaluate the Effect of Danoprevir/Ritonavir on the Pharmacokinetics of Escitalopram and S-Demethylcitalopram in Healthy Volunteers

Healthy Volunteer

United States
Hoffmann-La Roche

Completed

A Study of Ritonavir-Boosted Danoprevir in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients of Asian Origin With Chronic Hepatitis C Genotype 1 With or Without Cirrhosis

Hepatitis C, Chronic

Taiwan, Korea, Republic of, Thailand
Hoffmann-La Roche

Completed

A Study of Potential Drug-Drug Interaction Between Efavirenz and Danoprevir With Low Dose Ritonavir in Healthy Volunteers

Healthy Volunteer

United States
Hoffmann-La Roche

Completed

A Study on the Interaction Between Danoprevir/Ritonavir and Methadone

Healthy Volunteer

United States
Hoffmann-La Roche

Completed

A Study to Evaluate The Effects of Two Different Meal Types, Omeprazole And Ranitidine On Danoprevir Pharmacokinetics When Coadministered With Ritonavir in Healthy Volunteers

Healthy Volunteer

United States

3

Subscribe